

FORM 7

MONTHLY PROGRESS REPORT

Name of CNSX Issuer: **BioMark Diagnostics Inc.** (the "Issuer").

Trading Symbol: **BUX**

Number of Outstanding Listed Securities: **54,436,543**

Date: **April 4, 2017**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the CNSX Policies. *If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the CNSX.ca website.*

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the CNSX Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "**Issuer**" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer continued its business developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively.

2. Provide a general overview and discussion of the activities of management.

- **BioMark along with Dr. Andrew Maksymuik presented to Genome Canada and selected external reviewers and were requested to resubmit a more targeted application in July 2017. The new application will be made with support from Genome Prairie, , Saint Boniface, Mitacs and Dr. Maksymuik from CancerCare Manitoba**
- **BioMark presented at #BCTECH Summit, during the Investment Showcase that was held on March 15th 2017 at Vancouver Convention Centre. BioMark is following up with both local and international investors that showed interest in capital investment**
- **BioMark received preliminary patent approval for 2 applications in China and Europe in regards to the use of 2 new substrates for spermine spermidine acetyl transferase application and the use of gene expression for cancer detection and quantification.**
- **Additional breast cancer and control samples that were planned to be tested at The Metabolomics Innovation Centre (TMIC) later in March / April 2017 were cancelled following reported instrument breakdown of AB Sciex system across the globe. AB Sciex supplies all major labs with its QTRAP system that is a workhorse in metabolomics research. System recall and upgrade is underway.**
- **Dr. David Chen from UBC and BioMark will be applying for a major program under Natural Sciences and Engineering Research Council of Canada (NSERC) called CRD in late April to help with a development of a new and more sensitive quantification technology that might reduce the costs associated with lab costs for BioMark's assay.**
- **BioMark presented to Hon. Bill Morneau, Minister of Finance, Canada on March 28th at Innovation Boulevard Foundation in Surrey. The showcase included other leading BC based companies that were selected that are doing innovative work in area of healthcare.**

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or Production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Not applicable.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not applicable.

5. Describe any new business relationships entered into between the Issuer, the

Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Not applicable.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not applicable.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the dispositions was to a Related Person of the Issuer and provide details of the relationship.

Not applicable.

8. Describe the acquisition of new customers or loss of customers.

Not applicable.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

The Issuer continues to file trademark and patents in specific jurisdictions for all its patents. Review of the filings and opinions from patent offices are being reviewed as needed.

10. Report on any employee hiring, terminations or lay-offs with details of anticipated length of lay-offs.

Not applicable.

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not applicable.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not applicable.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Not applicable.

14. Provide details of any securities issued and options or warrants granted.

Not applicable.

15. Provide details of any loans to or by Related Persons.

Not applicable.

16. Provide details of any changes in directors, officers or committee members.

Not applicable.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are detailed in Item 17 of the Issuer's Annual Listing Statement "Risk Factors".

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there/were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CSE that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CSE Requirements (as defined in CSE Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: April 4, 2017

Rashid Ahmed

Name of Director or Senior
Officer

"Rashid Ahmed"

Signature

President & CEO
Official Capacity

Issuer Details Name of Issuer BioMark Diagnostics Inc.	For Month End March 2017	Date of Report YY/MM/D 2017/04/01
Issuer Address : 165-10551 Shellbridge Way		
City/Province/Postal Code Richmond, BC V6X 2W8	Issuer Fax No. (604) 282-6567	Issuer Telephone No. (604) 282-6567
Contact Name Rashid Ahmed	Contact Position CEO	Contact Telephone No. (604) 282-6567
Contact Email Address info@biomarkdiagnostics.com	Web Site Address www.biomarkdiagnostics.com	